Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 16/20 | 0.56 |
| ▸ | GPR174 | Q9BXC1 | 10/20 | 0.56 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30244695 | 1.00 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL29715574 | 1.00 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL22219423 | 1.00 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL21067706 | 1.00 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL13863415 | 1.00 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| Dexfosfoserine SCHEMBL28051238 | 0.84 | PGK1 (0.53) | P2RY10GPR174GPR34 | |
| SCHEMBL30244795 | 0.83 | P2RY10 (0.41) | P2RY10GPR174GPR34 | |
| SCHEMBL29556656 | 0.83 | P2RY10 (0.41) | P2RY10GPR174GPR34 | |
| SCHEMBL13618513 | 0.83 | P2RY10 (0.60) | P2RY10GPR174GPR34 | |
| SCHEMBL12284729 | 0.83 | SMN1; SMN2 (0.46) | P2RY10GPR174GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265522-A | Lipid-based RNA formulations suitable for treatment | 生物技术欧洲股份公司 | 2024-06-28 | — | — | CN | claimed |
| US-20030026831-A1 | Anionic liposomes for delivery of bioactive agents | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-02-06 | — | — | US | claimed |
| EP-3548002-B1 | HYDROPHILIC FLUORINATED MOLECULES FOR LIPOSOMAL 19F MRI PROBES WITH UNIQUE MR SIGNATURES | Texas Childrens Hospital (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-118265522-A | Lipid-based RNA formulations suitable for treatment | 生物技术欧洲股份公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024107474-A1 | CONTROLLED LIPID SELF-ASSEMBLY FOR SCALABLE MANUFACTURING OF NEXT-GENERATION IMMUNE STIMULATING COMPLEXES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240165029-A1 | ASSISTED LOADING OF HYDROPHOBIC MOLECULES INTO LIPOSOMES | UNIVERSITY OF CONNECTICUT | 2024-05-23 | — | — | US | disclosed |
| WO-2024035783-A2 | SULFUR-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF FOR DELIVERY OF NUCLEIC ACIDS | POSEIDA THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023180183-A1 | LIPOSOMAL COMPOSITIONS | R.G.C.C. Holdings AG (CH) | 2023-09-28 | — | — | WO | disclosed |
| EP-4248949-A1 | LIPOSOMAL COMPOSITIONS | R.G.C.C. Holdings AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| US-20230158507-A1 | BIOLOGICAL MEMBRANE-BASED SENSOR | MCMASTER UNIVERSITY (CA) | 2023-05-25 | — | — | US | disclosed |
| CN-115350154-A | Lipid cake for preparing anesthetic composition and use thereof | 美商TLC生物医药公司 | 2022-11-18 | — | — | CN | disclosed |
| WO-2006002050-A1 | PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE | ENCORE THERAPEUTICS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005016308-A1 | MACROLIDES CONTAINING OIL-IN-WATER EMULSIONS | SD PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20030026831-A1 | Anionic liposomes for delivery of bioactive agents | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-02-06 | — | — | US | disclosed |
| EP-0943096-A4 | A PROTEIN PREPARATION THAT MEDIATES Ca2+ -DEPENDENT TRANSBILAYER MOVEMENT OF PLASMA MEMBRANE PHOSPHOLIPID AND INHIBITORS THEREOF | BLOOD CT RES FOUNDATION (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1030866-A2 | METHODS AND COMPOSITIONS TO ALTER THE CELL SURFACE EXPRESSION OF PHOSPHATIDYLSERINE AND OTHER CLOT-PROMOTING PLASMA MEMBRANE PHOSPHOLIPIDS | BLOOD CENTER RESEARCH FOUNDATION (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0943096-A1 | A PROTEIN PREPARATION THAT MEDIATES Ca2+ -DEPENDENT TRANSBILAYER MOVEMENT OF PLASMA MEMBRANE PHOSPHOLIPID AND INHIBITORS THEREOF | BLOOD CENTER RESEARCH FOUNDATION (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1999019352-A2 | METHODS AND COMPOSITIONS TO ALTER THE CELL SURFACE EXPRESSION OF PHOSPHATIDYLSERINE AND OTHER CLOT-PROMOTING PLASMA MEMBRANE PHOSPHOLIPIDS | BLOOD CENTER RESEARCH FOUNDATION (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1997037225-A1 | A PROTEIN PREPARATION THAT MEDIATES Ca2+-DEPENDENT TRANSBILAYER MOVEMENT OF PLASMA MEMBRANE PHOSPHOLIPID AND INHIBITORS THEREOF | BLOOD CENTER RESEARCH FOUNDATION (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0181465-A1 | Blood coagulation inhibiting proteins, process for preparing them and their use | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165029-A1 | ASSISTED LOADING OF HYDROPHOBIC MOLECULES INTO LIPOSOMES | LIPA, MICA, TLR9 | P2RY10 2925/4885GPR174 3846/4885GPR34 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.